Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03165955
Other study ID # KX-ORAX-007
Secondary ID U1111-1176-4228
Status Completed
Phase Phase 1
First received
Last updated
Start date May 9, 2017
Est. completion date November 22, 2018

Study information

Verified date March 2022
Source Athenex, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, open-label, single-arm PK study in patients for whom paclitaxel treatment is indicated.


Description:

This is a multicenter, open-label, single-arm PK study in approximately 24 breast cancer patients for whom paclitaxel treatment is indicated. The study contains 3 periods: the Screening / Baseline Period, the Treatment Period, and the Follow-up Period. A Final Visit will occur within 7 days of the last dose of study treatment. If subjects achieve stable disease (SD), partial response (PR), or complete response (CR) at the end of the Treatment Period, they may continue Oraxol treatment in a separate extension study.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date November 22, 2018
Est. primary completion date November 22, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Signed written informed consent 2. Women =18 years of age on day of consent 3. Breast cancer in patients for whom treatment with IV paclitaxel at 80 mg/m2 as monotherapy has been recommended by their oncologist 4. Measurable disease as per RECIST v1.1 criteria 5. Adequate hematological status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) maintain: - Absolute neutrophil count (ANC) =1.5 x 10^9/L - Platelet count =100 x 10^9/L - Hemoglobin (Hgb) =9 g/dL 6. Adequate liver function - Total bilirubin of =1.5 mg/dL - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3 x upper limit of normal (ULN) or =5 x ULN if liver metastasis is present - Alkaline phosphatase (ALP) =3 x ULN or =5 x ULN if bone metastasis is present - Gamma glutamyl transferase (GGT) <10 x ULN 7. Adequate renal function as demonstrated by serum creatinine =1.5 x ULN 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 9. Life expectancy of at least 3 months 10. Willing to fast for 6 hours before and 2 hours after Oraxol administration on all treatment days 11. Willing to abstain from alcohol consumption for 3 days before the first dose of study drug through the completion of the second inpatient PK sampling period 12. Willing to refrain from caffeine consumption for 12 hours before each inpatient dosing period through the completion of protocol-specified PK sampling for that week 13. Subjects must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment. 14. Subjects who are of childbearing potential must have a negative serum pregnancy test at Screening and within 96 hours before dosing. Exclusion Criteria: 1. Have not recovered to = Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs) 2. If previously treated with a taxane (paclitaxel or docetaxel) as part of anthracycline-based adjuvant chemotherapy or for metastatic disease, the subject relapsed less than 1 year following treatment 3. Subjects unable to swallow study medication in its intact form or have clinically significant malabsorption syndrome 4. Only site of metastatic disease is unmeasurable according to RECIST v1.1 criteria 5. Known CNS metastasis, including leptomeningeal involvement 6. Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer 7. Are currently receiving other medications intended for the treatment of their malignancy 8. Women who are pregnant or breastfeeding 9. Taking prohibited medications: 10. Use of warfarin. Subjects receiving warfarin who are otherwise eligible and who may be appropriately managed with low molecular weight heparin, in the opinion of the Investigator, may be enrolled in the study provided they are switched to low molecular weight heparin at least 7 days prior to receiving study treatment. 11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements 12. Known allergic reaction or intolerance to study medication components 13. Known allergic reaction or intolerance to contrast media 14. Subjects who, in the Investigator's opinion, are not suitable for participation in this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oraxol
HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules

Locations

Country Name City State
Taiwan China Medical University Hospital Taichung
Taiwan National Taiwan University Hospital Taipei
Taiwan Shuang Ho Hospital Taipei
Taiwan Taipei Medical University Hospital Taipei
Taiwan Taipei Veterans Generla Hospital Taipei
Taiwan Tri-Service General Hospital Taipei

Sponsors (2)

Lead Sponsor Collaborator
Athenex, Inc. PharmaEssentia

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary PK Parameters for paclitaxel_AUC (0-52) PK parameters were summarized using the mean, SD PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary PK Parameters for paclitaxel_Cmax PK parameters were summarized using the mean, SD PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary PK Parameters for paclitaxel_Ctrough(24) PK parameters were summarized using the mean, SD PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary PK Parameters for paclitaxel_Ctrough(48) PK parameters were summarized using the mean, SD PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary PK Parameters for paclitaxel_Cmax(0-24) PK parameters were summarized using the mean, SD PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary PK Parameters for paclitaxel_Cmax(24-48) PK parameters were summarized using the mean, SD PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary PK Parameters for paclitaxel_Cmax(48-52) PK parameters were summarized using the mean, SD PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary PK Parameters for paclitaxel_tmax(0-24) PK parameters were summarized using the median, minimum, maximum PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary PK Parameters for paclitaxel_tmax(24-48) PK parameters were summarized using the median, minimum, maximum PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Primary PK Parameters for paclitaxel_tmax(48-52) PK parameters were summarized using the median, minimum, maximum PK sampling timepoints: predose, and at 1, 2, 3, and 4 hours after dosing of Day 1, 2, 3 at Week 1 and 4
Secondary Safety of Oraxol in Breast Cancer Patients Safety was assessed by evaluating treatment-emergent adverse events (TEAEs) including SAEs, laboratory evaluations (hematology, blood chemistry, and urinalysis), vital signs, physical examinations, and electrocardiograms (ECGs). From enrollment through study completion, approximately 17 weeks
Secondary Response Rate Tumor response rate and 95% confidence interval (CI) were evaluated based on the number of subjects with any post-baseline CR or PR per RECIST 1.1 as assessed by the Investigator and the ICRRC. From baseline through study completion, around 21 weeks
Secondary Progression-free Survival PFS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.
The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation
From baseline through study completion, around 21 weeks
Secondary Overall Survival OS was analyzed based on the Response Evaluable Population. The Kaplan-Meier (KM) method was used to estimate the medians of these variables with 95% CIs.
The Response Evaluable Population included all subjects who received at least 1 dose of study treatment and had at least 1 posttreatment tumor response evaluation
From baseline through study completion, around 21 weeks
See also
  Status Clinical Trial Phase
Completed NCT02944604 - The Efficacy and Safety of PEG-rhG-CSF(Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy Phase 4
Completed NCT03012152 - A Comparative Study Between Oncoplastic Breast Surgery and Standard Conservative Surgery:Margin Status and Patient Satisfaction N/A
Terminated NCT04168957 - An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007 Phase 1
Recruiting NCT02967146 - Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Axillary Dissection for Breast Cancer Phase 3
Completed NCT02958332 - Effects of a Videogame-based Program on Women With Lymphedema Secondary to Breast Cancer N/A
Completed NCT03030677 - Establishing Technique for PECS2 Catheter Insertion N/A
Completed NCT03066947 - SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Phase 1/Phase 2
Recruiting NCT02992574 - Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer N/A
Completed NCT02964234 - Empowering Latinas to Obtain Breast Cancer Screenings N/A
Completed NCT02996240 - Breast, Omega 3 Free Fatty Acid, Ph 0 N/A
Completed NCT03010371 - Presential Vs Online Group-based Psychosocial Treatment for Breast Cancer Survivors. N/A
Completed NCT02209857 - The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy N/A
Completed NCT03014076 - Immunotherapy Vaccine and Herceptin in Breast Cancer Phase 1
Terminated NCT02975128 - Minimal Invasive Breast Cancer Excision Using the Breast Lesion Excision System Under Ultrasound Guidance N/A
Active, not recruiting NCT03121248 - Outcome of 15 Versus 5 Fractions in Adjuvant Breast Radiotherapy in Women Over 65 Years N/A
Active, not recruiting NCT02997384 - Feasibility of Breast Cancer Risk Evaluation in Women From the General Population N/A
Completed NCT03012893 - Identification of C7; Evaluations of 2 Sonographic Methods Using a Transverse and a Sagittal Scan. N/A
Completed NCT03023007 - Study Evaluating the Efficacy of Loco-regional Anaesthesia PECS on Chronic Pain of a Mastectomy N/A
Completed NCT04993040 - A PK Study of Oraxol in Breast Cancer Patients Phase 1
Completed NCT02992067 - CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer